Melatonin and succinate reduce rat liver mitochondrial dysfunction in diabetes

Journal of Physiology and Pharmacology

Volumn 62, Issue 4, 2011, Pages 421-427

  Zavodnik, Ilya B ^a,b   Lapshina, E A ^a   Cheshchevik, V T ^a,b   Dremza, I K ^a   Kujawa, J ^c   Zabrodskaya, S V ^a   Reiter, R J ^d  

^a INSTITUTE OF BIOCHEMISTRY   (Belarus)

^b YANKA KUPALA STATE UNIVERSITY OF GRODNO   (Belarus)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d University of Texas Health Science Center at San Antonio   (United States)

Author keywords

Antioxidants; Bioenergetics; Experimental diabetes; Liver; Melatonin; Mitochondria; Succinate

Indexed keywords

CATALASE; GLUTATHIONE TRANSFERASE; MELATONIN; OXOGLUTARATE DEHYDROGENASE; OXYGEN; SUCCINIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPLASM; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; LIVER CELL; LIVER DYSFUNCTION; LIVER MITOCHONDRION; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OXYGEN CONSUMPTION; RAT; STREPTOZOCIN DIABETES;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; KIDNEY; LIVER; LIVER FUNCTION TESTS; MALE; MELATONIN; MITOCHONDRIA, LIVER; ORGAN SIZE; OXIDATIVE STRESS; RATS; RATS, WISTAR; STREPTOZOCIN; SUCCINATES;

EID: 82155181576     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
2. Baynes JW, Thorpe SR. Role of oxidative stress in diabetes complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
3. Schaffer SW, Azuma J, Mozaffari M. Role of antioxidant activity of taurine in diabetes. Can J Physiol Pharmacol 2009; 87: 91-99.
4. Goldstein BJ, Mahadev K, Wu X. Insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets. Diabetes 2005; 54: 311-321.
5. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
6. Green K, Brand MD, Murphy P. Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 2004; 53: 110-118.
7. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-414.
8. Moreira PI, Cardoso SM, Pereira CM, Santos MS, Oliveira CR. Mitochondria as a therapeutic target in Alzheimers disease and diabetes. CNS Neurol Disord Drug Targets 2009; 8: 492-511.
9. Dey A, Swaminathan K. Hyperglycemia-induced mitochondrial alterations in liver. Life Sci 2010; 87: 197-214.
10. Vengerovskii AI, Khazanov VA, Eskina KA, Vasilyev KY. Effects of silymarin (hepatoprotector) and succinic acid (bioenergy regulator) on metabolic disorders in experimental diabetes mellitus. Bull Exp Biol Med 2007; 144: 53-56.
11. Tretter L, Szabados G, Ando A, Horvath I. Effect of succinate on mitochondrial lipid peroxidation. 2. The protective effect of succinate against functional and structural changes induced by lipid peroxidation. J Bioenerg Biomembr 1987; 19: 31-44.
12. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44: 175-200.
13. 2+-mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 2010; 48: 20-38.
14. Paradies G, Petrosillo G, Paradies V, Reiter RJ, Ruggiero FM. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
15. Sudnikovich EJ, Maksimchik YZ, Zabrodskaya SV, et al. Melatonin attenuates metabolic disorders due to streptozotocin-induced diabetes in rats. Eur J Pharmacol 2007; 569: 180-187.
16. Nishida S. Metabolic effects of melatonin on oxidative stress and diabetes mellitus. Endocrine 2005; 27: 131-136.
17. Drobnik J, Slotwinska D, Olczak S, et al. Pharmacological doses of melatonin reduce the glycosaminoglycan level within the infarcted heart scar. J Physiol Pharmacol 2011; 62: 29-35.
18. Johnson D, Lardy HA. Isolation of liver or kidney mitochondria. Meth Enzymol 1967; 10: 94-101.
19. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Ellman G. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
21. Rossi R, Cardaioli E, Scaloni A, Ammmiooni G, Di Simplicio P. Thiol groups in proteins as endogenous reductants to determine glutathione-protein mixed disulphides in biological systems. Biochim Biophys Acta 1993; 1164: 289-298.
22. Stocks J, Dormandy TL. The autoxidation of human red cell lipids induced by hydrogen peroxide. Br J Haematol 1971; 20: 95-111.
23. Nulton-Persson AC, Szweda LI. Modulation of mitochondrial function by hydrogen peroxide. J Biol Chem 2001; 276: 23357-23361.
24. Martinez JI, Launay JM, Dreux C. A sensitive fluorimetric microassay for the determination of glutathione peroxidase activity. Application to human blood platelets. Anal Biochem 1979; 98: 154-159.
25. Habig WH, Pabst MJ, Jacoby WB. Glutathione-Stransferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-7139.
26. Aebi H. Catalase in vitro. In Oxygen Radicals in Biological Systems, L Packer (ed). Orlando, Academic Press, 1984, pp. 121-126.
27. Ferreira FM, Palmeira CM, Seica R, Moreno AJ, Santos MS. Diabetes and mitochondrial bioenergetics alterations with age. J Biochem Mol Toxicol 2003; 17: 214-222.
28. Lashin O, Romani A. Mitochondria respiration and susceptibility to ischemia-reperfusion injury in diabetic hearts. Arch Biochem Biophys 2003; 420: 298-304.
29. Moreira PI, Santos MS, Moreno AJ, Proenca T, Seica R, Oliveira CR. Effect of sreptozotocin-induced diabetes on rat brain mitochondria. J Neuroendocrinol 2004; 16: 32-38.
30. Sangle GV, Chowdhury SK, Xie X, Stelmack GL, Halayko AJ, Shen GX. Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated LDL. Free Radic Biol Med 2010; 48: 781-790.
31. Tan DX, Manchester LC, Fuentes-Broto L, Paredes SD, Reiter RJ. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011; 12: 167-188.
32. Fahien LA, MacDonald MJ. The succinate mechanism of insulin release. Diabetes 2002; 51: 2669-2676.
33. He W, Miao FG, Linn DC, et al. Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 2004; 429: 188-193.
34. Memon RA, Bessman SP, Mohan C. Impaired mitochondrial metabolism and reduced amphibolic Krebs cycle activity in diabetic rat hepatocytes. Biochem Mol Biol Int 1995; 37: 1079-1089.
35. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
36. Gallano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51: 1-16.
37. Reiter RJ, Tan DX, Mayo JC, Sainz RM, Leon J, Czarnocki Z. Melatonin as an antioxidant: biochemical mechanisms and pathophysiological implications in humans. Acta Biochim Pol 2003; 50: 1129-1146.
38. Lopez A, Garcia JA, Escames G, et al. Melatonin protects the mitochondria from oxidative damage reducing oxygen consumption, membrane potential, and superoxide anion production. J Pineal Res 2009; 46: 188-198.
39. Maksimchik YZ, Dremza IK, Lapshina EA, et al. Rat liver mitochondria impairments under acute carbon tetrachlorideinduced intoxication. Effects of melatonin. Biochemistry (Moscow) Suppl Series A: Membrane and Cell Biology 2010; 4: 187-195.
40. Peschke E, Wolgast S, Bazwinsky I, Ponicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res 2008; 45: 439-448.
41. Peschke E, Hofmann K, Bahr I, et al. The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia 2011; 54: 1831-1840.
42. Picinato MC, Haber EP, Cipolla-Neto J, Curi R, de Oliveira Carvalho CR, Carpinelli AR. Melatonin inhibits insulin secretion and decreases PKA levels without interfering with glucose metabolism in rat pancreatic islets. Pineal Res 2002; 33: 156-160.
43. Peschke E, Hofman K, Ponicke K, Wedekind D, Muhlbauer E. Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonism in type 1 and type 2 diabetes. J Pineal Res 2011; doi: 10.1111/j.1600-079X.2011.00951.x. Epub ahead of print.
44. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004; 18: 869-871.
45. Negi G, Kumar A, Kaundal RK, Gulati A, Sharma SS. Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010; 58: 585-592.